Hypo-S).Conclusion: The above data indicate that the effect of losartan on the electrophysiological changes induced by stretch of atrial myocytes is associated with blocking of AT1 receptor, and is beneficial for the treatment of AF that is often accompanied by the expansion of atrial myocytesand the increase of effective refractory period. (Anatol J Cardiol 2020; 23: 35-40)
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Objective: The present study aims to investigate the effect of losartan, an selective angiotensin II type 1 receptor (AT1R) blocker, on both theincrease of IKs current and shortening of action potential duration (APD) induced by stretch of atrial myocytes, and to uncover the mechanismunderlying the treatment of fibrillation (AF) by AT1R blockers.Methods: Hyposmotic solution (Hypo-S) was applied in the guinea pig atrial myocytes to simulate cell stretch, then patch-clamp technique wasapplied to record the IKs and APD in atrial myocytes.Results: Hypo-S increased the IKs by 105.6%, while Hypo-S+1-20 µM of losartan only increased the IKs by 70.3-75.5% (p<0.05 vs.
📊
Key Findings & Data:Meanwhile, Hypo-S shortened APD90 by 20.2%, while Hypo-S+1-20 µM of losartan shortened APD90 by 13.03-14.56% (p<0.05 vs.
💡
Conclusion & Impact:Hypo-S).Conclusion: The above data indicate that the effect of losartan on the electrophysiological changes induced by stretch of atrial myocytes is associated with blocking of AT1 receptor, and is beneficial for the treatment of AF that is often accompanied by the expansion of atrial myocytesand the increase of effective refractory period. (Anatol J Cardiol 2020; 23: 35-40)
🔬Design:Research Article
📍Scope:2020 Verileri
⚙️Variables:Domain Parameters
Özet
Objective: The present study aims to investigate the effect of losartan, an selective angiotensin II type 1 receptor (AT1R) blocker, on both theincrease of IKs current and shortening of action potential duration (APD) induced by stretch of atrial myocytes, and to uncover the mechanismunderlying the treatment of fibrillation (AF) by AT1R blockers.Methods: Hyposmotic solution (Hypo-S) was applied in the guinea pig atrial myocytes to simulate cell stretch, then patch-clamp technique wasapplied to record the IKs and APD in atrial myocytes.Results: Hypo-S increased the IKs by 105.6%, while Hypo-S+1-20 µM of losartan only increased the IKs by 70.3-75.5% (p<0.05 vs. Hypo-S). Meanwhile, Hypo-S shortened APD90 by 20.2%, while Hypo-S+1-20 µM of losartan shortened APD90 by 13.03-14.56% (p<0.05 vs. Hypo-S).Conclusion: The above data indicate that the effect of losartan on the electrophysiological changes induced by stretch of atrial myocytes is associated with blocking of AT1 receptor, and is beneficial for the treatment of AF that is often accompanied by the expansion of atrial myocytesand the increase of effective refractory period. (Anatol J Cardiol 2020; 23: 35-40)
🔖
Cite This Article
GAO, J., Tian, Y., XIE, X., ZHAO, J., LIU, C., SHENG, Y., CAO, F. (2020). Losartan inhibits hyposmotic-induced increase of I Ks current and shortening of action potential duration in guinea pig atrial myocytes. The Anatolian Journal of Cardiology, Cilt: 23 - Sayı: 1, 35–40. https://ajindex.com/articles/365175
Nagayama T, Hirooka Y, Kishi T, Mukai Y, Inoue S, Takase S, et al. Blockade of brain angiotensin II type I receptor inhibits the development of atrial fibrillation in hypertensive rats. Am J Hypertens 2015; 28: 444-51
Fujita M, Cheng XW, Inden Y, Shimano M, Yoshida N, Inoue A, et al. Mechanisms with clinical implications for atrial fibrillation-associated remodeling: cathepsin K expression, regulation, and therapeutic target and biomarker. J Am Heart Assoc 2013; 2: e000503
Ehrlich JR, Nattel S. Novel approaches for pharmacological management of atrial fibrillation. Drugs 2009; 69: 757-74
Spinarova L, Spinar J. Pharmacotherapy of dilated cardiomyopathy. Curr Pharm Des 2015; 21: 449-58
Madrid AH, Peng J, Zamora J, Marin I, Bernal E, Escobar C, et al. The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials. Pacing Clin Electrophysiol 2004; 27: 1405-10
Takii E, Inage T, Yoshida T, Ohe M, Gondo T, Haraguchi G, et al. Beneficial effects of losartan for prevention of paroxysmal atrial fibrillation in patients with sick sinus syndrome: analysis with memory function of pacemaker. Heart Vessels 2016; 31: 402-7
Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45: 1832-9
Novo G, Guttilla D, Fazio G, Cooper D, Novo S. The role of the reninangiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS. Br J Clin Pharmacol 2008; 66: 345-51
Schneider MP, Hua TA, Böhm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by rennin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010; 55: 2299-307
Goette A, Schön N, Kirchhof P, Breithardt G, Fetsch T, Häusler KG, et al. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol 2012; 5: 43-51
Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002; 54: 230-46
Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002; 415: 219-26
Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induc